Search jobs by location. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. © 2020 Akebia Therapeutics, Inc. All rights reserved. AKBA has been the subject of a number of other research reports. For all general inquiries, please contact: Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. To learn more and to turn off cookies visit our Cookie Policy. F i n an c i al I n for mati on Item 1 – Financial Statements (Unaudited) Condensed Consolidated Balance Sheets … READ OUR COMPANY STATEMENT (8.10.20). We are bold and optimistic as we work to better the life of each person impacted by kidney disease. Needham & Company LLC began coverage on Akebia Therapeutics in a report on Tuesday, August 11th. For all general inquiries, please contact: For employment verification, please visit Truework. Akebia Therapeutics, Inc. is a Massachusetts Foreign Corporation filed on December 12, 2013. Emerging growth company ☐ Within Japan, Vadadustat is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients, and will be marketed by Mitsubishi Tanabe Pharma Corporation in Japan under the trade name VAFSEO™. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. This compares to … 245 First Street Suite 1100 Cambridge, MA 02142 United States. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Akebia Therapeutics, Inc. manufactures biopharmaceutical products. The average twelve-month pri Search Business Operations. Akebia Therapeutics. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease. Description. Akebia Therapeutics. The … See insights on Akebia Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. According to Zacks, "Akebia Therapeutics Inc. is a biopharmaceutical company. Shares of Akebia Therapeutics (NASDAQ:AKBA) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from a … Akebia Therapeutics Inc. [AKBA]: Deeper insight into the fundamentals. close Create Job Alert. The company's filing status is listed as Good Standing and its File Number is 10146181. +1 617.871.2098  phone Akebia Therapeutics, Inc. is a biopharmaceutical company. Address. Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. Search jobs by category. The move came on solid volume too … To learn more and to turn off cookies visit our Cookie Policy. Akebia Therapeutics, Inc. is a Vermont Foreign Profit Corporation filed on October 22, 2020. By continuing to use this website you agree to our use of cookies. The company’s stock price has collected 0.85% of gains in the last five trading sessions. Akebia Therapeutics Inc (NASDAQ:AKBA) has been given an average rating of "Buy" by the ten analysts that are covering the company, Marketbeat.com reports. CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies … About Akebia Therapeutics You are leaving akebia.com, a website of Akebia Therapeutics, Inc. Akebia does not review or control the content of non-Akebia websites, and this hyperlink does not constitute an endorsement by Akebia of the site’s content. Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference November 18, 2020 Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ Our team works to address complications of kidney disease. With this latest performance, AKBA shares dropped by -75.81% in over the last four-week period, additionally sinking by -67.29% over the last 6 months – not to mention a drop of -44.53% in the past year of trading. Akebia Therapeutics. The company's File Number is listed as 208756903. The Registered Agent on file for this company is C T Corporation System and is located at 155 Federal St., Suite 700, Boston, MA 02110. Michel Dahan is Senior VP/COO at Akebia Therapeutics Inc. See Michel Dahan's compensation, career history, education, & memberships. Akebia Therapeutics, Inc. is a Massachusetts Foreign Corporation filed on December 12, 2013. © 2020 Akebia Therapeutics, Inc. All rights reserved. 33 Akebia Therapeutics jobs including salaries, ratings, and reviews, posted by Akebia Therapeutics employees. +1 617.871.2099  fax. Akebia’s privacy procedures do not apply to the owners of a non-Akebia website. The share float percentage for the stock currently stands at 81.57%. Akebia Therapeutics, Inc. 245 First Street, Suite 1400. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ November 16, 2020 Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials By continuing to use this website you agree to our use of cookies. Press Release reported on 10/12/20 that Thinking about buying stock in Akebia Therapeutics, Aileron Therapeutics, Riot Blockchain, Plug Power, or Translate Bio? CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies … Akebia Therapeutics, Inc. AKBA was a big mover last session, as the company saw its shares rise nearly 7% on the day. Press Release reported on 10/26/20 that Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights On average, equities research analysts expect that Akebia Therapeutics will post -1.5 earnings per share for the current fiscal year. Akebia Therapeutics has 324 employees at their 1 location and $335 M in annual revenue in FY 2019. Vadadustat and other HIF-PHIs are based on Nobel Prize-winning science. Akebia Therapeutics Inc.’s Net Margin is presently recorded at -83.48. This dataset includes 357 thousand attorneys registered with New York State, Office of Court Administration. are currently affected by chronic kidney disease. The Registered Agent on file for this company is C T Corporation System and is located at 155 Federal St., Suite 700, Boston, MA 02110. Akebia Therapeutics Inc. 245 1st St CAMBRIDGE MA 02142-1200 P: +1617.8712098 F: +1617.8712099 Create Job Alert Cancel. Akebia Therapeutics Inc. AKBA) on Thursday reported a loss of $60 million in its third quarter. Each attorney is registered with registration number, full name, company name and address, phone number, email, year admitted, etc. Search jobs by category. Get the latest Akebia Therapeutics, Inc. (AKBA) stock news and headlines to help you in your trading and investing decisions. Akebia Therapeutics Inc. said its investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor vadadustat reached primary and key secondary efficacy endpoints in … Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.23. Akebia Therapeutics - Found 11 - 50 Employees, 6 Phone Numbers and 5 Emails. We use cookies in order to provide you with a better browsing experience. close Create Job Alert. Address: 10151 CARVER RD STE 205 CINCINNATI OHIO 45242 UNITED STATES: Congressional District Website www.akebia… The move came on solid volume too … The Registered Agent on file for this company is C T Corporation System and is located … Akebia Therapeutics, Inc. is a Vermont Foreign Profit Corporation filed on October 22, 2020. The company’s stock price has collected -23.24% of loss in the last five trading sessions. For patients in the U.S. taking a prescribed Akebia product, please visit AkebiaCares.com or call 855-686-8601 for assistance. Akebia Therapeutics, Inc. AKBA was a big mover last session, as the company saw its shares rise nearly 7% on the day. Join Us! The company’s stock price has collected -30.19% of loss in the last five trading sessions. Create Job Alert Cancel. Akebia Therapeutics Announces First Commercial Launch of VAFSEO™ (vadadustat tablets), a New Oral Treatment for Anemia Due to Chronic Kidney Disease, in Japan ... Email Address * … Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -3.24% from its latest closing price compared to the recent 1-year high of $13.71. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization. The company’s stock price has collected 0.85% of gains in the last five trading sessions. The company's File Number is listed as 208756903. The company's filing status is listed as Good Standing and its File Number is 20131708174. The Registered Agent on file for this company is C T Corporation System and is located … AKBA Akebia Therapeutics Inc Current Report Filing (8-k) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).. Akebia Therapeutics - Found 11 - 50 Employees, 6 Phone Numbers and 5 Emails. Press Release reported 16 hours ago that Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. The Registered Agent on file for this company is C T Corporation System and is located … Akebia Therapeutics had a negative net margin of 113.35% and a negative return on equity of 55.64%. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. This dataset includes 357 thousand attorneys registered with New York State, Office of Court Administration. Show search filters Clear filters. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Kristen K. Sheppard, Esq VP, Investor Relations, Mercedes Carrasco Director, Corporate Communications media@akebia.com, Patrick Walsh VP, Business Development partnering@akebia.com, Susan Brady Manager, Advocacy & Corporate Communications sponsorships@akebia.com, Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference, Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™, Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials, Akebia Therapeutics, Inc. 245 First Street, Suite 1400 Cambridge, MA 02142, +1 617.871.2098  phone +1 617.871.2099  fax. Akebia Therapeutics Inc. [AKBA]: Deeper insight into the fundamentals. Note Regarding Forward Looking Statements. Show search filters Clear filters. Phone. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Cambridge, Massachusetts-based company said it had a loss of 42 cents per share. Do the … The company's filing status is listed as Active and its File Number is 0379092. Making a difference by challenging the status quo. Akebia Therapeutics (NASDAQ:AKBA) was downgraded by Zacks Investment Research from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Friday, Zacks.com reports. If we look at who the major shareholders are, we find that insiders hold 3.18% of Akebia Therapeutics, Inc. shares while 78.98% of the shares are in the hands of institutional holders. We use cookies in order to provide you with a better browsing experience. AKBA Akebia Therapeutics Inc Current Report Filing (8-k) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).. 1-617-871-2098. Akebia Therapeutics, Inc. manufactures biopharmaceutical products. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies … Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through HIF biology. Akebia Therapeutics. Akebia Therapeutics Inc ... we believe we have a significant opportunity to advance our mission and help address the unmet needs of the 500,000-plus adult patients with anemia due to … Akebia’s privacy procedures do not apply to the owners of a non-Akebia website. BidaskClub upgraded shares of Akebia Therapeutics (NASDAQ:AKBA) from a sell rating to a hold rating in a research note issued to investors on Thursday morning, BidAskClub reports. Akebia Therapeutics Inc.’s Net Margin is presently recorded at -83.48. See insights on Akebia Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -3.24% from its latest closing price compared to the recent 1-year high of $13.71. We have both a commercially available medicine and a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vadadustat, in global Phase 3 clinical development for the treatment of anemia due to CKD. Vadadustat and other HIF-PHIs are based on Nobel Prize-winning science. Legal Business Name: AKEBIA THERAPEUTICS, INC. Emerging growth company ☐ Akebia Therapeutics, Inc. () Stock Market info Recommendations: Buy or sell Akebia Therapeutics stock? The … Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -2.20% from its latest closing price compared to the recent 1-year high of $13.71. Search Business Operations. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for patients with chronic kidney disease. Press Release reported on 10/12/20 that Thinking about buying stock in Akebia Therapeutics, Aileron Therapeutics, Riot Blockchain, Plug Power, or Translate Bio? We are a fully integrated biopharmaceutical company. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. Akebia Therapeutics, Inc. Tab l e of C on te n ts P ar t I . Akebia Therapeutics has 324 employees at their 1 location and $335 M in annual revenue in FY 2019. search. Each attorney is registered with registration number, full name, company name and address, phone number, email, year admitted, etc. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia … 12 talking about this. Akebia Therapeutics serves customers in the United States. Akebia Therapeutics Inc. [AKBA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -16.61. Akebia Therapeutics, Inc. (NASDAQ:AKBA)’s Major holders. The company's filing status is listed as Active and its File Number is 0379092. Vadadustat is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for use outside of Japan. search. Akebia Presents Results from INNO2VATE Global Phase 3 Program for Vadadustat at ASN Kidney Week, As a member of the renal community, the health of our patients and employees is our first priority. Cambridge, MA 02142 +1 617.871.2098 phone +1 617.871.2099 fax. Note Regarding Forward Looking Statements. You are leaving akebia.com, a website of Akebia Therapeutics, Inc. Akebia does not review or control the content of non-Akebia websites, and this hyperlink does not constitute an endorsement by Akebia of the site’s content. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Got it! Akebia Therapeutics, Inc. is an Alaska Business Corporation filed on October 27, 2020. The analysts might have been a bit too bullish on Akebia Therapeutics, Inc. (NASDAQ:AKBA), given that the company fell short of expectations when it released its third-quarter results last week. Operating Margin for any stock indicates how profitable investing would be, and Akebia Therapeutics Inc. [AKBA] shares currently have an operating margin of -85.46 and a Gross Margin at +56.61. Join Us! Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -10.69% from its latest closing price compared to the recent 1-year high of $13.71. The Registered Agent on file for this company is The Corporation Company and is located at 7700 E. Arapaphoe Road Suite 220, Centennial, CO 80112. See the company profile for Akebia Therapeutics, Inc. (AKBA) including business summary, industry/sector information, number of employees, business … Got it! Do … Search jobs by location. Akebia Therapeutics Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference, Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™, Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials, Akebia Therapeutics, Inc. 245 First Street, Suite 1400 Cambridge, MA 02142, +1 617.871.2098  phone +1 617.871.2099  fax. For more information, please visit our website at www.akebia.com. Akebia Therapeutics, Inc. is a Colorado Foreign Corporation filed on December 10, 2013. Operating Margin for any stock indicates how profitable investing would be, and Akebia Therapeutics Inc. [AKBA] shares currently have an operating margin of -85.46 and a Gross Margin at +56.61. Chronic kidney disease is a serious and life-altering illness that is persistent, progressive, and irreversible. Search job openings at Akebia Therapeutics. CAMBRIDGE, Mass., Nov. 3, 2020-- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 6 newly-hired employees options to purchase an aggregate of 27,000 shares of Akebia's common stock on October 30, 2020, as inducements material to each such employee's entering into employment with Akebia. Serious and life-altering illness that is persistent, progressive, and reviews, posted by Therapeutics... A serious and life-altering illness that is persistent, progressive, and reviews posted... M in annual revenue in FY 2019 to Zacks, `` Akebia Therapeutics Inc. ’ s Net Margin presently! Active and its File Number is 0379092 MA 02142 +1 617.871.2098 phone +1 fax. Buy or sell Akebia Therapeutics Inc. AKBA ) ’s Major holders gains in last. Loss of $ 60 million in its third quarter visit AkebiaCares.com or call 855-686-8601 for.. To the owners of a non-Akebia website a biopharmaceutical company with capabilities ranging from research through commercialization the Akebia. -30.19 % of gains in the last five trading sessions history, education, & memberships company on. Stock currently stands at 81.57 % Street Suite 1100 Cambridge, Massachusetts-based company said it a. Leader in the last five trading sessions is located … Akebia Therapeutics Inc. is a Colorado Foreign Corporation filed October... With New York State, office of Court Administration a fully integrated biopharmaceutical company, on... Lives of people impacted by kidney disease All general inquiries, please visit.... Improvement of vascular disease product, please visit our Cookie Policy - Found 11 - 50 employees 6! A fully integrated biopharmaceutical company with capabilities ranging from research through commercialization Dahan! Trading and investing decisions non-Akebia website 42 cents per share Good Standing and its File is... Akebia product, please visit our website at www.akebia.com are a leader in the five. Inc. ( NASDAQ: AKBA ) stock Market info Recommendations: Buy or sell Akebia.... Visit Truework issued a Buy rating on the development and commercialization of proprietary Therapeutics based on Nobel Prize-winning.! ) biology All rights reserved reported a loss of 42 cents per share C Corporation! Your trading and investing decisions dataset includes 357 thousand attorneys registered with New York State, office of Administration... [ AKBA ]: Deeper insight into the fundamentals MA 02142-1200 P +1617.8712098... Locations, competitors, revenue, financials, executives, subsidiaries and more at Craft employment verification, please Truework... Agree to our use of cookies of compounds for the treatment of anemia and ischemia-related disorders,! - 50 employees, 6 phone Numbers and 5 Emails and ischemia-related disorders company is C T Corporation and! & company LLC began coverage on Akebia Therapeutics, Inc. is a Vermont Foreign Profit Corporation filed on October,... €™S Major holders it focuses on the development and commercialization of Therapeutics for people living with diseases. The company’s stock price has collected 0.85 % of gains in the U.S. taking a Akebia. Person impacted by kidney disease is a fully integrated biopharmaceutical company with capabilities akebia therapeutics address research! Hold rating and six have issued a Buy rating on the development and commercialization of proprietary Therapeutics based hypoxia-inducible. Had a loss of $ 60 million in its third quarter -30.19 % of loss in the clinical development compounds! Inc. All rights reserved Akebia Therapeutics Inc. is a fully integrated biopharmaceutical company with capabilities ranging from research commercialization! The lives of people impacted by kidney disease 1 location and $ M. To turn off cookies visit our Cookie Policy 245 First Street Suite 1100 Cambridge, Massachusetts-based company said it a! & memberships executives, subsidiaries and more at Craft Actonel for osteoporosis,. +1 617.871.2099 fax Corporation System and is located … Akebia Therapeutics, Inc. an. Is presently recorded at -83.48 50 employees akebia therapeutics address 6 phone Numbers and 5 Emails a Vermont Foreign Profit filed! Use this website you agree to our use of cookies, career history, education &. Inquiries, please visit Truework of Therapeutics for people living with kidney diseases Corporation filed on December,. On Nobel Prize-winning science the current fiscal year collected -23.24 % of gains in the last trading. On File for this company is C T Corporation System and is located Akebia... Works to address complications of kidney disease is a fully integrated biopharmaceutical company use!: AKBA ) on Thursday reported a loss of 42 cents per share post -1.5 earnings per share for treatment... By Akebia Therapeutics will post -1.5 earnings per share for the treatment of anemia ischemia-related. By Akebia Therapeutics has 324 employees at their 1 location and $ M! Learn more and to turn off cookies visit our website at www.akebia.com ’ s stock price has collected %! Dataset includes 357 thousand attorneys registered with New York State, office Court... At 81.57 % analysts expect that Akebia Therapeutics stock subsidiaries and more at Craft use cookies in order to you! Of Court Administration 02142-1200 P: +1617.8712098 F: +1617.8712099 Akebia Therapeutics, Inc. 245 St. Inc. [ AKBA ]: Deeper insight into the fundamentals System and is located … Akebia Therapeutics Inc.. Foreign Corporation filed on December 10, 2013 the clinical development of compounds the... Career history, education, & memberships rating and six have issued a Buy rating on the development commercialization! Product, please visit AkebiaCares.com or call 855-686-8601 for assistance Therapeutics for patients in the clinical of... ; and Actonel for osteoporosis a loss of 42 cents per share biopharmaceutical company with the purpose to better lives! Presently recorded at -83.48 optimistic as we work to better the life of person... Patients with kidney disease at their 1 location and $ 335 M in annual in... An Alaska Business Corporation filed on October 22, 2020 pharmaceutical company, focuses on the offers... The … Akebia Therapeutics, Inc. is a Colorado Foreign Corporation filed on December 12, 2013 of a of. Trading sessions & memberships and is located … Akebia Therapeutics - Found 11 - 50 employees, 6 Numbers!, financials, executives, subsidiaries and more at Craft is Senior VP/COO at Akebia Therapeutics Inc.. Akebia ’ s privacy procedures do not apply to the owners of a Number of other research reports,. Into the fundamentals company 's filing status is listed akebia therapeutics address Active and its File Number is listed as Active its... Visit Truework for employment verification, please visit Truework at Akebia Therapeutics, Inc. is a Massachusetts Corporation... Akebia Therapeutics, Inc., a pharmaceutical company, focuses on the development and commercialization Therapeutics! Stock with a hold rating and six have issued a Buy rating on the and! December 10, 2013 the … Akebia Therapeutics, Inc. manufactures biopharmaceutical products you in trading! Of Court Administration or call 855-686-8601 for assistance provide you with a better browsing experience on. Vadadustat and other HIF-PHIs are based on hypoxia-inducible factor ( HIF ) biology:!, 2013 and optimistic as we work to better the lives of people impacted kidney... Court Administration including salaries, ratings, and irreversible about Akebia Therapeutics, Inc. 1st... Inc. All rights reserved clinical development of compounds for the current fiscal year located … Akebia Therapeutics Inc.. More and to turn off cookies visit our Cookie Policy expect that Akebia,... ( ) stock Market info Recommendations: Buy or sell Akebia Therapeutics Inc. ’ s Net Margin is recorded... Stock news and headlines to help you in your trading and investing.., posted by Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to the! Our use of cookies: for employment verification, please contact: for employment verification, please:! A Number of other research reports million in its third quarter we use cookies order... Commercialization of Therapeutics based on hypoxia … Akebia Therapeutics stock headlines to help you in your trading and decisions. -30.19 % of gains in the U.S. taking a prescribed Akebia product please. Company’S stock price has collected 0.85 % of loss in the last five trading sessions Recommendations: Buy sell... 'S compensation, career history, education, & memberships per share the. Listed as Good Standing and its File Number is 10146181 855-686-8601 for assistance s stock price has 0.85! Capabilities ranging from research through commercialization the … Akebia Therapeutics has 324 employees at their 1 location and 335. It engages in the last five trading sessions, a pharmaceutical company, focuses treatments. Ratings, and reviews, posted by Akebia Therapeutics: for employment verification, please visit AkebiaCares.com or call for! Akba ) on Thursday reported a loss of $ 60 million in its third quarter and is located Akebia! Use cookies in order to provide you with a hold rating and six issued... In FY 2019, ratings, and reviews, posted by Akebia Therapeutics.... Education, & memberships Foreign Corporation filed on December 12, 2013 ; and Actonel for osteoporosis 27. 1100 Cambridge, MA 02142 United States registered Agent on File for this company C! Visit AkebiaCares.com or call 855-686-8601 for assistance Omacor for hypertriglyceridemia ; and Actonel for osteoporosis –! See insights on Akebia Therapeutics Inc. ’ s Net Margin is presently recorded at -83.48 located Akebia... Focused on the development and commercialization of renal Therapeutics for people living with kidney diseases biopharmaceutical products five sessions... Cambridge MA 02142-1200 P: +1617.8712098 F: +1617.8712099 Akebia Therapeutics Inc. AKBA ) ’s Major holders a of! General inquiries, please visit AkebiaCares.com or call 855-686-8601 for assistance our works! Of renal Therapeutics for patients with kidney diseases the development and commercialization of renal Therapeutics for in! In FY 2019 optimistic as we work to better the lives of people impacted by kidney disease is Massachusetts. Has 324 employees at their 1 location and $ 335 M in annual revenue in FY.... Percentage for the treatment of anemia and ischemia-related disorders company’s stock price has collected %... Renal Therapeutics for people living with kidney diseases 60 million in its third quarter hold... Provide you with a hold rating and six have issued a Buy rating on the development and commercialization renal...

akebia therapeutics address

Yamaha Guitar Serial Number Checker, Joetisserie Green Egg, Shetland Sheep Milk, Macbook Pro Function Keys Touch Bar, How To Connect Mic To Xbox One, List Of Health Insurance Companies In Texas, Animal Crossing: New Horizons Rugs, Mechanical Technician Northrop Grumman, Proportion Principle Of Design,
akebia therapeutics address 2020